Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

By Jonathan A. Ledermann, P. Harter, C. Gourley, M. Friedlander, I. Vergote, G. Rustin, Clare L. Scott, W. Meier, R. Shapira-Frommer, T. Safra and 8 more. The Lancet Oncology, 2014

1,266 citations recorded by the source corpus.

Subfields: Genetics, Oncology, Reproductive Medicine

View Paper: https://www.semanticscholar.org/paper/67d5b53382312f5d44bf5fcc0a1b3e0aede55573

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Charles Swanton
2. Eytan Ruppin
3. Andrea Soltoggio
4. Abhishek Niroula
5. Mauno Vihinen
6. Nouf S. Al-Numair
7. Andrew C. R. Martin

In Oncology

1. Nikolaus Schultz
2. Charles Swanton

In Reproductive Medicine

1. Abel Gonzalez-Perez
2. Núria López-Bigas
3. Jonathan A. Ledermann
4. C. Sessa
5. D. Querleu
6. M. Mirza

Citations in the corpus

• A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) (2018, background): “These trials demonstrated improved outcome and therefore germline BRCA1 or BRCA2 mutations are tier I targets in these diseases [31, 32].”
• Precision Oncology: The Road Ahead (2017, background): “Poly (ADP-ribose) polymerase PARP inhibitors in tumors with homologous recombination deficiency [15]).”
• ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. (2019, background): “Olaparib maintenance was permitted beyond progression, and both olaparib and niraparib studies led to an increase in the time to the next line of treatment, a clinically meaningful endpoint.(35) 36 38 Toxicity of PARP inhibitors is generally manageable through dose reductions and interruptions of th”
• Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer (2019, neutral): “Leukopenia 89 (24) 34 (9) 87 (23) 44 (12) 112 (30) 66 (18)”